Orgenesis to acquire regenerative medicine company Koligo Therapeutics

This article was originally published here

Koligo is involved in the development of personalised cell therapies using the cells of the patient. The company already commercialised its first commercial product Kyslecel for the treatment

The post Orgenesis to acquire regenerative medicine company Koligo Therapeutics appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply